molecular-oncology-hero-New
HNL Genomics

Molecular Oncology

Our Molecular Oncology division uses molecular testing to identify the genetic abnormalities that drive cancer and allows for targeted therapy and a better understanding of the patient's prognosis

This testing revolutionizes the standard of patient care, changing how diseases are diagnosed and treated. HNL Lab Medicine's Molecular Oncology department utilizes sophisticated molecular techniques, including next-generation sequencing for comprehensive profiling of both solid tumors and hematologic malignancies.

Common Molecular Oncology Tests

NGS Solid Tumor Panel -161 genes; DNA & RNA Sequencing; sub-panels available on request (Lung, Colon, GIST, Melanoma etc.)

NGS Solid Tumor with TMB and MSI The NGS Solid Tumor with TMB and MSI panel offers a  comprehensive assessment of key biomarkers to  enhance treatment outcomes and optimize patient  care. In addition to identifying relevant DNA and RNA variants implicated in various tumor types, it accurately measures  key current immuno-oncology biomarkers: microsatellite  instability (MSI) and tumor mutational burden (TMB).

  • Turnaround Time - 14 Days
  • 523 genes for DNA 
  • 55 genes for RNA 
  • 99% Analytical Sensitivity
Genes tested
Hotspot Genes (87)
Full-Length Genes (48)
Copy Number Genes (43)
Gene Fusions (Inter- and Intra-genic)

AKT1, AKT2, AKT3, ALK, AR, ARAF, AXL, BRAF, BTK, CBL, CCND1, CDK4, CDK6, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERCC2, ESR1, EZH2, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, H3F3A, HIST1H3B, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KIT, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAPK1, MAX, MDM4, MED12, MET, MTOR, MYC, MYCN, MYD88, NFE2L2, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPP2R1A, PTPN11, RAC1, RAF1, RET, RHEB, RHOA, ROS1, SF3B1, SMAD4, SMO, SPOP, SRC, STAT3, TERT, TOP1, U2AF1, XPO1


ARID1A, ATM, ATR, ATRX, BAP1, BRCA1, BRCA2, CDK12, CDKN1B, CDKN2A, CDKN2B, CHEK1, CREBBP, FANCA, FANCD2, FANCI, FBXW7, MLH1, MRE11A, MSH2, MSH6, NBN, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, PALB2, PIK3R1, PMS2, POLE, PTCH1, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RB1, RNF43, SETD2, SLX4, SMARCA4, SMARCB1, STK11, TP53, TSC1, TSC2

AKT1, AKT2, AKT3, ALK, AR, AXL, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPARG, RICTOR, TERT


AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT

BRAF p.V600E, p.V600K, p.V600R
  • Turnaround Time - 7 days
NGS Myeloid Panel – 69 genes; DNA & RNA sequencing
  • Turnaround Time – 14 days
  • Variants tested: Single Nucleotide Variants (SNV), Small Insertions/Deletions (Indels), Fusions
Genes tested
Hotspot Genes (23)
Full Genes (17)
Fusion Driver Genes (29)
Expression Genes (5)
Expression Control Genes (5)
ABL1, KRAS, BRAF, MPL, CBL, MYD88, CSF3R, NPM1, DNMT3A, NRAS, FLT3, PTPN11, GATA2, SETBP1, HRAS, SF3B1, IDH1, SRSF2, IDH2, U2AF1, JAK2, WT1, KITASXL1, PRPF8, BCOR, RB1, CALR, RUNX1, CEBPA, SH2B3, ETV6, STAG2, EZH2, TET2, IKZF1, TP53, NF1, ZRSR2, PHF6ABL1, HMGA2, NUP214, ALK, JAK2, PDGFRA, BCL2, KMT2A (MLL), RARA, CCND1, MECOM, RBM15, CREBBP, MET, RUNX1, EGFR, MLLT10, TCF3, ETV6, MLLT3, TFE3, FGFR1, MYBL1, FGFR2, MYH11, FUS, NTRK3BAALC, MECOM, MYC, SMC1A, WT1EIF2B1, FBXW2, PSMB2, PUM1, TRIM27

FLT3-ITD and FLT3-TKD
  • Turnaround Time – 2 days
BCR/ABL1 Quantitative
  • Turnaround Time – 4 days
JAK2 p.V617F
  • Turnaround Time –4 days